However, when using the treatments with proven survival benefits, including temozolomide, radiation, and tumor treating fields, progression-free survival and overall survival can vary widely across patients and cannot be reliably predicted by the usual prognostic features alone (age, MGMT methylation status, extent of resection, and performance status). Here, MGMT is linked to neoplasm.